|
1
|
Watanabe T, Muro K, Ajioka Y, Hashiguchi
Y, Ito Y, Saito Y, Hamaguchi T, Ishida H, Ishiguro M, Ishihara S,
et al: Japanese Society for Cancer of the Colon and Rectum:
Japanese Society for Cancer of the Colon and Rectum (JSCCR)
guidelines 2016 for the treatment of colorectal cancer. Int J Clin
Oncol. 23:1–34. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Moertel CG: Chemotherapy for colorectal
cancer. N Engl J Med. 330:1136–1142. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Saltz LB, Cox JV, Blanke C, Rosen LS,
Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta
N, et al: Irinotecan Study Group: Irinotecan plus fluorouracil and
leucovorin for metastatic colorectal cancer. N Engl J Med.
343:905–914. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Colucci G, Gebbia V, Paoletti G, Giuliani
F, Caruso M, Gebbia N, Cartenì G, Agostara B, Pezzella G, Manzione
L, et al: Gruppo Oncologico Dell'Italia Meridionale: Phase III
randomized trial of FOLFIRI versus FOLFOX4 in the treatment of
advanced colorectal cancer: A multicenter study of the Gruppo
Oncologico Dell'Italia Meridionale. J Clin Oncol. 23:4866–4875.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Goldberg RM, Sargent DJ, Morton RF, Fuchs
CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts
SR: A randomized controlled trial of fluorouracil plus leucovorin,
irinotecan, and oxaliplatin combinations in patients with
previously untreated metastatic colorectal cancer. J Clin Oncol.
22:23–30. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hochster HS, Hart LL, Ramanathan RK,
Childs BH, Hainsworth JD, Cohn AL, Wong L, Fehrenbacher L, Abubakr
Y, Saif MW, et al: Safety and efficacy of oxaliplatin and
fluoropyrimidine regimens with or without bevacizumab as first-line
treatment of metastatic colorectal cancer: Results of the TREE
Study. J Clin Oncol. 26:3523–3529. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jonker DJ, O'Callaghan CJ, Karapetis CS,
Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et
al: Cetuximab for the treatment of colorectal cancer. N Engl J Med.
357:2040–2048. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cunningham D, Humblet Y, Siena S, Khayat
D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype
C, et al: Cetuximab monotherapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer. N Engl J Med.
351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
De Roock W, Piessevaux H, De Schutter J,
Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL,
Peeters M, Humblet Y, et al: KRAS wild-type state predicts survival
and is associated to early radiological response in metastatic
colorectal cancer treated with cetuximab. Ann Oncol. 19:508–515.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lièvre A, Bachet JB, Le Corre D, Boige V,
Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, et al:
KRAS mutation status is predictive of response to cetuximab therapy
in colorectal cancer. Cancer Res. 66:3992–3995. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Di Nicolantonio F, Martini M, Molinari F,
Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L,
Frattini M, Siena S, et al: Wild-type BRAF is required for response
to panitumumab or cetuximab in metastatic colorectal cancer. J Clin
Oncol. 26:5705–5712. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kasper S, Reis H, Ziegler S, Nothdurft S,
Mueller A, Goetz M, Wiesweg M, Phasue J, Ting S, Wieczorek S, et
al: Molecular dissection of effector mechanisms of RAS-mediated
resistance to anti-EGFR antibody therapy. Oncotarget.
8:45898–45917. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Van Cutsem E, Köhne CH, Láng I, Folprecht
G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D,
Tejpar S, et al: Cetuximab plus irinotecan, fluorouracil, and
leucovorin as first-line treatment for metastatic colorectal
cancer: Updated analysis of overall survival according to tumor
KRAS and BRAF mutation status. J Clin Oncol. 29:2011–2019. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yoshida M, Hatano N, Nishiumi S, Irino Y,
Izumi Y, Takenawa T and Azuma T: Diagnosis of gastroenterological
diseases by metabolome analysis using gas chromatography-mass
spectrometry. J Gastroenterol. 47:9–20. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Spratlin JL, Serkova NJ and Eckhardt SG:
Clinical applications of metabolomics in oncology: a review. Clin
Cancer Res. 15:431–440. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fernández-Ochoa Á, Quirantes-Piné R,
Borrás-Linares I, Gemperline D, Riquelme Alarcón ME, Beretta L and
Segura-Carretero A: PRECISESADS Clinical Consortium: Urinary and
plasma metabolite differences detected by HPLC-ESI-QTOF-MS in
systemic sclerosis patients. J Pharm Biomed Anal. 162:82–90. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jeong A, Fiorito G, Keski-Rahkonen P,
Imboden M, Kiss A, Robinot N, Gmuender H, Vlaanderen J, Vermeulen
R, Kyrtopoulos S, et al: EXPOsOMICS Consortium: Perturbation of
metabolic pathways mediates the association of air pollutants with
asthma and cardiovascular diseases. Environ Int. 119:334–345. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kobayashi T, Nishiumi S, Ikeda A, Yoshie
T, Sakai A, Matsubara A, Izumi Y, Tsumura H, Tsuda M, Nishisaki H,
et al: A novel serum metabolomics-based diagnostic approach to
pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 22:571–579.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sakai A, Suzuki M, Kobayashi T, Nishiumi
S, Yamanaka K, Hirata Y, Nakagawa T, Azuma T and Yoshida M:
Pancreatic cancer screening using a multiplatform human serum
metabolomics system. Biomark Med. 10:577–586. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hirata Y, Kobayashi T, Nishiumi S,
Yamanaka K, Nakagawa T, Fujigaki S, Iemoto T, Kobayashi M, Okusaka
T, Nakamori S, et al: Identification of highly sensitive biomarkers
that can aid the early detection of pancreatic cancer using
GC/MS/MS-based targeted metabolomics. Clin Chim Acta. 468:98–104.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nishiumi S, Kobayashi T, Kawana S, Unno Y,
Sakai T, Okamoto K, Yamada Y, Sudo K, Yamaji T, Saito Y, et al:
Investigations in the possibility of early detection of colorectal
cancer by gas chromatography/triple-quadrupole mass spectrometry.
Oncotarget. 8:17115–17126. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Redalen KR, Sitter B, Bathen TF, Grøholt
KK, Hole KH, Dueland S, Flatmark K, Ree AH and Seierstad T: High
tumor glycine concentration is an adverse prognostic factor in
locally advanced rectal cancer. Radiother Oncol. 118:393–398. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Terazawa T, Nishitani H, Kato K, Hashimoto
H, Akiyoshi K, Ito Y, Nakamoto A, Iwasa S, Nakajima TE, Hamaguchi
T, et al: Phase II study of cetuximab with irinotecan for KRAS
wild-type colorectal cancer in Japanese patients. Asia Pac J Clin
Oncol. 13:e132–e137. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
Organization for Research and Treatment of Cancer, National Cancer
Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fujigaki S, Nishiumi S, Kobayashi T,
Suzuki M, Iemoto T, Kojima T, Ito Y, Daiko H, Kato K, Shouji H, et
al: Identification of serum biomarkers of chemoradiosensitivity in
esophageal cancer via the targeted metabolomics approach.
Biomarkers Med. 12:827–840. 2018. View Article : Google Scholar
|
|
28
|
Yamashita Y, Nishiumi S, Kono S, Takao S,
Azuma T and Yoshida M: Differences in elongation of very long chain
fatty acids and fatty acid metabolism between triple-negative and
hormone receptor-positive breast cancer. BMC Cancer. 17:5892017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Youden WJ: Index for rating diagnostic
tests. Cancer. 3:32–35. 1950. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Birkemeyer C, Luedemann A, Wagner C, Erban
A and Kopka J: Metabolome analysis: The potential of in vivo
labeling with stable isotopes for metabolite profiling. Trends
Biotechnol. 23:28–33. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Narayanan A, Baskaran SA, Amalaradjou MAR
and Venkitanarayanan K: Anticarcinogenic properties of medium chain
fatty acids on human colorectal, skin and breast cancer cells in
vitro. Int J Mol Sci. 16:5014–5027. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huether A, Höpfner M, Baradari V, Schuppan
D and Scherübl H: EGFR blockade by cetuximab alone or as
combination therapy for growth control of hepatocellular cancer.
Biochem Pharmacol. 70:1568–1578. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yamasaki M, Soda S, Sakakibara Y, Suiko M
and Nishiyama K: The importance of 1,2-dithiolane structure in
α-lipoic acid for the downregulation of cell surface β1-integrin
expression of human bladder cancer cells. Biosci Biotechnol
Biochem. 78:1939–1942. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Djukovic D, Zhang J and Raftery D:
Colorectal cancer detection using targeted LC-MS metabolic
profiling. Methods Mol Biol. 1765:229–240. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Delphan M, Lin T, Liesenfeld DB,
Nattenmüller J, Böhm JT, Gigic B, Habermann N, Zielske L,
Schrotz-King P, Schneider M, et al: Associations of branched-chain
amino acids with parameters of energy balance and survival in
colorectal cancer patients: Results from the ColoCare Study.
Metabolomics. 2018:222018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Uchiyama K, Yagi N, Mizushima K,
Higashimura Y, Hirai Y, Okayama T, Yoshida N, Katada K, Kamada K,
Handa O, et al: Serum metabolomics analysis for early detection of
colorectal cancer. J Gastroenterol. 52:677–694. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jansen RJ, Robinson DP, Frank RD, Anderson
KE, Bamlet WR, Oberg AL, Rabe KG, Olson JE, Sinha R, Petersen GM,
et al: Fatty acids found in dairy, protein and unsaturated fatty
acids are associated with risk of pancreatic cancer in a
case-control study. Int J Cancer. 134:1935–1946. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sato T, Kameyama T and Inoue H:
Association of reduced levels of serum 1,5-Anhydro-d-glucitol with
carotid atherosclerosis in patients with type 2 diabetes. J
Diabetes Complications. 28:348–352. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang X, Häring M-F, Rathjen T, Lockhart
SM, Sørensen D, Ussar S, Rasmussen LM, Bertagnolli MM, Kahn CR and
Rask-Madsen C: Insulin resistance in vascular endothelial cells
promotes intestinal tumour formation. Oncogene. 36:4987–4996. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Meyerhardt JA, Sato K, Niedzwiecki D, Ye
C, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, et
al: Dietary glycemic load and cancer recurrence and survival in
patients with stage III colon cancer: Findings from CALGB 89803. J
Natl Cancer Inst. 104:1702–1711. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Larsson SC, Kumlin M, Ingelman-Sundberg M
and Wolk A: Dietary long-chain n-3 fatty acids for the prevention
of cancer: A review of potential mechanisms. Am J Clin Nutr.
79:935–945. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hall MN, Chavarro JE, Lee IM, Willett WC
and Ma J: A 22-year prospective study of fish, n-3 fatty acid
intake, and colorectal cancer risk in men. Cancer Epidemiol
Biomarkers Prev. 17:1136–1143. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Siena L, Cipollina C, Di Vincenzo S,
Ferraro M, Bruno A, Gjomarkaj M and Pace E: Electrophilic
derivatives of omega-3 fatty acids counteract lung cancer cell
growth. Cancer Chemother Pharmacol. 81:705–716. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Benais-Pont G, Dupertuis YM, Kossovsky MP,
Nouet P, Allal AS, Buchegger F and Pichard C: Omega-3
polyunsaturated fatty acids and ionizing radiation: Combined
cytotoxicity on human colorectal adenocarcinoma cells. Nutrition.
22:931–939. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Cai F, Dupertuis YM and Pichard C: Role of
polyunsaturated fatty acids and lipid peroxidation on colorectal
cancer risk and treatments. Curr Opin Clin Nutr Metab Care.
15:99–106. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yang K, Li H, Dong J, Dong Y and Wang CZ:
Expression profile of polyunsaturated fatty acids in colorectal
cancer. World J Gastroenterol. 21:2405–2412. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hardy S, Langelier Y and Prentki M: Oleate
activates phosphatidylinositol 3-kinase and promotes proliferation
and reduces apoptosis of MDA-MB-231 breast cancer cells, whereas
palmitate has opposite effects. Cancer Res. 60:6353–6358.
2000.PubMed/NCBI
|
